Bicycle Therapeutics shares rise 5.90% intraday after announcing new board members and expanding its clinical advisory board.

Bicycle Therapeutics Plc rose 5.90% in intraday trading, with the company announcing the addition of Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, to its Board of Directors. Dr. Swanton is the current chair of Bicycle Therapeutics' Clinical Advisory Board and leads the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute. His research focuses on tumor evolution and cancer diversity, which could potentially benefit the company's oncology-focused programs.